Clinical Therapeutics · 2019 · 26 citations · 12 references
MedicinePharmacologyPharmacotherapyAntimicrobial PharmacologyAntimicrobial PharmacotherapyPharmacovigilanceAntibiotic ResistanceAntimicrobial PharmacodynamicsMultidrug ResistancePharmacokinetics Of AntimicrobialsCardiac RepolarizationCephalosporin TherapyMultidrug-resistant Gram-negative BacteriaMultidrug-resistant OrganismsMultidrug-resistant PathogensQt Interval AnalysisQt Interval Assessment
PURPOSE: Cefiderocol is a novel siderophore cephalosporin with potent activity against gram-negative bacteria, including multidrug-resistant strains. This Phase I study was conducted to assess the tolerability of single-ascending doses of cefiderocol (part 1) and the effect of cefiderocol on cardiac repolarization, assessed using the electrocardiographic corrected QT interval (QTcF) and other ECG parameters (part 2), in healthy adult subjects. METHODS: Part 1 was a randomized, double-blind, placebo-controlled, single-ascending dose study in healthy adult male and female subjects. Part 2 was a 4-period crossover study in which subjects received a single 2-g dose of cefiderocol (therapeutic dose), a single 4-g dose of cefiderocol (supratherapeutic dose), or saline (placebo), each infused over 3 hours, and a single oral 400-mg dose of moxifloxacin. In each treatment period, continuous cardiac monitoring was used to assess the effects of cefiderocol on ECG parameters. The QT interval corrected using the Fridericia formula (QTcF) was the primary ECG parameter; the time-matched placebo- and baseline-adjusted (dd)-QTcF interval was the primary end point. The plasma pharmacokinetic properties of cefiderocol were calculated on the basis of concentration-time profiles in all evaluable subjects. FINDINGS: of cefiderocol. Both doses of cefiderocol were well tolerated. All adverse events were mild in severity, with no deaths or serious adverse events reported. IMPLICATIONS: Overall, therapeutic and supratherapeutic doses of cefiderocol had no apparent clinically significant effect on the QTcF.
12
Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · The Lancet Infectious Diseases · 2018 · 404 citations
Akinobu Ito, Toru Nishikawa, Shuhei Matsumoto et al. · Antimicrobial Agents and Chemotherapy · 2016 · 333 citations · Full text
Meredith Hackel, Masakatsu Tsuji, Yoshinori Yamano et al. · Antimicrobial Agents and Chemotherapy · 2017 · 196 citations · Full text
J Dobiás, Valérie Dénervaud‐Tendon, Laurent Poirel et al. · European Journal of Clinical Microbiology & Infectious Diseases · 2017 · 150 citations